MedTrace Logo

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

NCT00293436 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2012-09-17

No results posted yet for this study

Summary

RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by blocking blood flow to the tumor.

PURPOSE: This phase I/II trial is studying the side effects and best dose of giving celecoxib together with erlotinib and to see how well they work in treating patients with liver cancer.

Conditions

Interventions

DRUG

celecoxib

DRUG

erlotinib hydrochloride

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

Principal Investigators

  • Alan P. Venook, MD · University of California, San Francisco

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293436 on ClinicalTrials.gov